DAB486interleukin-2
Alternative Names: Interleukin-2 fusion toxin (DAB486)Latest Information Update: 13 Dec 1995
At a glance
- Originator Seragen
- Developer Eli Lilly and Company; Seragen
- Class Antihyperglycaemics; Antineoplastics; Antirheumatics; Antivirals
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections; Inflammatory bowel diseases; Kaposi's sarcoma; Leukaemia; Lymphoma; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 13 Dec 1995 Ajinomoto's license has been discontinued
- 23 Aug 1995 Discontinued-II for HIV infections treatment in USA (IV)
- 23 Aug 1995 Discontinued-II for Kaposi's sarcoma in USA (IV)